Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches
Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a newly defined disease entity characterized by aggressive clinical behavior, diagnostic complexity, and poor prognosis. Given its rarity and heterogeneous histological presentation, establishing a definitive diagnosis can be challenging and relies heavily on comprehensive molecular and immunohistochemical evaluation. Here, illustrating the challenges highlighted by a real-world case, we describe the diagnostic pathway leading to SMARCA4-UT identification and discuss the differential diagnosis of thoracic tumors, relevant molecular evaluations, the molecular basis of SMARCA4-UT, and treatment implications. Recognition of this recently described entity is crucial, as an accurate diagnosis-as demonstrated by our case-can guide effective therapy and facilitate enrollment in targeted clinical trials.
Authors
- Benjamin Herzberg (ORCID: https://orcid.org/0000-0002-3253-3106)
- Junmin Song (ORCID: https://orcid.org/0000-0002-6150-6529)
- Balázs Halmos (ORCID: https://orcid.org/0000-0001-7548-8360)
- A. Gersten (ORCID: https://orcid.org/0000-0001-7861-6639)
Institutions
- Albert Einstein College of Medicine (US)
- Montefiore Medical Center (US)
- Jacobi Medical Center (US)
- Columbia University (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf121
- Citations
- 2
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Merck
- AbbVie
- Boehringer Ingelheim
- Arcus Foundation
- BeiGene
- Apollomics
- Genentech
- Daiichi Sankyo Europe